<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01418287</url>
  </required_header>
  <id_info>
    <org_study_id>ILI002</org_study_id>
    <secondary_id>HHSN272200900003I</secondary_id>
    <nct_id>NCT01418287</nct_id>
  </id_info>
  <brief_title>Characterization of Influenza-like Illness in Mexico</brief_title>
  <official_title>An Observational Study to Characterize Children and Adults With Influenza Like Illness (ILI) in Mexico</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mexican Emerging Infectious Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Secretaria de Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Enfermedades Respiratorias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Pediatrics, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Dr. Manuel Gea González</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Infantil de Mexico Federico Gomez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mexican Emerging Infectious Diseases Clinical Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to characterize children and adults with influenza like symptoms and to determine
      risk factors for severe disease and death among those with H1N1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In March 2009, a new influenza A virus, novel H1N1 (commonly referred to as &quot;swine flu&quot;),
      began causing an increase in reports of influenza-like illness in North America. Although the
      virus subsequently spread rapidly around the world, the earliest reported outbreak of cases
      occurred in Mexico City, which is seen as the epicenter of the influenza pandemic, the
      world's first in 40 years.

      Many questions remain about this emerging pandemic and the virus causing it, the answers to
      which could better inform patient management and policy decisions both in Mexico and
      internationally. Sparse reliable clinical research data have been collected on the natural
      history of the disease, on the risk factors associated with severe disease, or on the
      severity of this pandemic influenza as compared to seasonal influenzas. This study is an
      initial step to better characterize individuals in Mexico who develop influenza-like illness
      (including illness caused by novel H1N1), to describe the clinical management of those
      individuals, and to assess their short-term outcome. The planned data collection will provide
      timely information to inform policy and guidelines for the local populations and governments
      involved and may also be used to design future ancillary studies of this influenza virus
      and/or studies of other emerging infectious diseases.

      The purpose of this observational study is to characterize individuals in Mexico who seek
      medical care for influenza-like illness (ILI) and to describe clinical course over a period
      of at least 28 days after enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize individuals who develop influenza-like illness, influenza A, and/or H1N1 or other viruses</measure>
    <time_frame>5 years</time_frame>
    <description>Characterize demographics, co-morbid conditions, prior influenza vaccination, the use of antivirals, and clinical course and treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>5 years</time_frame>
    <description>For all participants, to estimate the percentage who die</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>5 years</time_frame>
    <description>For all participants, to estimate the percentages who require hospitalization due to severe influenza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors</measure>
    <time_frame>5 years</time_frame>
    <description>For all participants, to determine risk factors for severe disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repository of oropharyngeal and nasal samples</measure>
    <time_frame>5 years</time_frame>
    <description>Establish a repository of oropharyngeal and nasal samples to determine a precise diagnosis, to molecularly characterize the virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repository of serum and PBMC</measure>
    <time_frame>5 years</time_frame>
    <description>Establish a repository of serum and PBMC to study biomarkers that predispose and correlate with severe influenza</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">5819</enrollment>
  <condition>Influenza-like Illness</condition>
  <arm_group>
    <arm_group_label>Hospitalized</arm_group_label>
    <description>Subjects who are hospitalized due to influenza-like illness</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-hospitalized</arm_group_label>
    <description>Subjects who are not hospitalized</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, PBMC and Nasopharingeal aspirates
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with influenza-like illness presenting to clinical sites in Mexico
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent by participant, or for pediatric participants, signed informed
             consent by parent/legal guardian and, where appropriate, signed assent by participant

          -  At least one respiratory symptom (e.g., shortness of breath, postnasal drip, cough)
             and

          -  One of the following criteria:

          -  Fever (≥ 38 °C by any method: oral, axillary, etc.) on examination or
             participant-reported fever (≥ 38° C) or feverishness in the past 24 hours

          -  One or more non-respiratory symptoms (e.g., malaise, headache, myalgia,chest pain)

          -  Consenting to provide aspirate or naso-pharyngeal swab

        Exclusion Criteria

          -  The onset of illness is more than 48 hours after hospitalization.

          -  Participants previously included in this study within the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Galindo Fraga, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Alejandra Ortiz Hernández, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Pediatría</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatría (INP)</name>
      <address>
        <city>México City</city>
        <state>México</state>
        <zip>CP 04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de México Federico Gómez (HIM)</name>
      <address>
        <city>México City</city>
        <state>México</state>
        <zip>CP 06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ)</name>
      <address>
        <city>México City</city>
        <state>México</state>
        <zip>CP 14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General y de Alta Especialidad Dr. Manuel Gea González</name>
      <address>
        <city>México City</city>
        <state>México</state>
        <zip>CP 14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias (INER)</name>
      <address>
        <city>México City</city>
        <state>México</state>
        <zip>CP 14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Luis Potosí (SLP):Hospital Central Dr. Ignacio Morones Prieto/Universidad Autónoma de San Luis Potosí</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>CP 78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

